Caring Ambassadors Hepatitis C Program Newsletter

www.HepCChallenge.org

March 2009

 

In The News

 

State seeks new laws following hepatitis outbreak panel

 “State lawmakers were in Las Vegas Saturday trying to pass new laws to strengthen regulations on health care. This comes after nearly 60,000 Clark County residents learned they had been exposed to hepatitis C at local medical clinics. Lawmakers are working on five bills they believe will help prevent the dangerous medical practices that happened at the Endoscopy Center of Southern Nevada. Saturday, a panel heard from victims and the medical community about their concerns and what they believe could be done to prevent a similar outbreak in the future.” Read more...

 

Probe attacks NHS 'Bad Blood' scandal

 “An inquiry has criticized the "procrastination" that led to a blood contamination scandal that killed nearly 2,000 people. Nearly 2,000 haemophilia patients died as result of "bad blood" transfusions. Some 4,670 patients who received "bad blood" transfusions during the 1970s and 80s were infected with Hepatitis C - of whom 1,243 were also infected with HIV.” Read more...

 

Romark reports promising data from hepatitis C virus study

 “Romark Laboratories, a privately held biopharmaceutical company, has announced encouraging results from international Phase I and II clinical trials evaluating a controlled release version of nitazoxanide in the treatment of chronic hepatitis C virus infection. In the Phase II study in treatment-naive patients infected with hepatitis C virus (HCV) genotype 4, 82% (n=17) and 100% (n=16) of patients receiving low and high doses of controlled release nitazoxanide, respectively, experienced undetectable serum HCV RNA (<12 IU/mL) after 12 weeks of combination therapy with peginterferon and ribavirin.” Read more...

 

Free needles for drug users 'good use of NHS money'

 “About 40% of drug users who inject are already infected with Hepatitis C. Providing free needles and syringes to people who inject heroin and cocaine is a cost-effective use of NHS money, the government's medicines watchdog said today. The National Institute for Health and Clinical Excellence (Nice) issued its first guidance on how harm reduction services for addicts should be run throughout England, suggesting combining non-judgmental needle exchange schemes with treatment to help users come off drugs.” Read more...

 

Forum addresses sex and hep C

“No one was more surprised than Tom Kelly when he was diagnosed – not once but twice – with hepatitis C. "I thought I was safe," he said at a recent community forum on sex and hep C. "I didn't do IV drugs and I thought I couldn't get it, but I got it anyway." Organized by an informal group of community members with the assistance of the San Francisco Department of Public Health, the January 27 forum at the LGBT Community Center brought out nearly 150 participants, underlining the growing concern about an emerging new epidemic.” Read more...

 

 

Natalie Cole's son to donate kidney to mom

 “Proving that he's a son that really knows how to step up to the plate for his mom, it's been reported that Natalie Cole's son may give her one of his kidneys. Cole was diagnosed with Hepatitis C about a year ago and now it seems she might need a kidney transplant, which would finally put an end to the dialysis treatments she goes through three times a week.” Read more...

 

Vertex will name Emmens to replace Boger as CEO

 “Vertex Pharmaceuticals Inc. said Thursday Matthew Emmens will become president, and eventually chairman and chief executive, of the company when founder Joshua Boger retires. Emmens, 57, takes the president position immediately and will become chairman and CEO in May. He has been a board member at Vertex since 2004.” Read more...

 

Tainted blood case study: 'My family believe my brother was murdered'

 “As a result of his hepatitis Mr Fielding developed cirrhosis of the liver and by October 1998 he needed a transplant. Despite a life plagued with ill health after a blood transfusion contaminated with hepatitis B and C, David Fielding, 53, considers himself the lucky one in his family. His brother, also a haemophiliac, contracted HIV after a similar transfusion and died in 1990 at the age of 46.” Read more...

 

Liver disease raised need for assistance

 “Liver transplant patient DeWayne Oaks talks about his recovery as he and his wife, Barbara, sit on their patio last week with their dogs in Lake Alfred. Confronted with the frightful diagnosis in 2006, Oaks, a trucker from Lake Alfred, sought medical treatment through the Veterans Administration. He spent the next few years in declining health and it cost him his job. Despite monetary assistance from friends and relatives, Oaks and his wife, Barbara, who stocks shelves at Wal-Mart, find themselves unable to meet expenses, prompting a request for help through The Ledger's Newspaper with a Heart program.” Read more...

 

Abbott and Enanta initiate phase I hepatitis trial

 “Abbott and Enanta Pharmaceuticals, a R&D company, have announced the advancement of their hepatitis C virus collaboration with a first-in-human study evaluating ABT-450, an oral protease inhibitor for the treatment of chronic HCV. The objectives of the trial include assessment of safety, tolerability and pharmacokinetics. ABT-450 was discovered as part of a worldwide alliance between Abbott and Enanta to discover, develop and commercialize protease inhibitors for the treatment of hepatitis C virus (HCV).” Read more...

 

In wake of hepatitis C crisis, legislators seek to improve health care

 “Gwendolyn Martin has hepatitis C. Her case was genetically linked to a patient who had underwent a procedure before her on Sept. 21, 2007, at the Endoscopy Center of Southern Nevada. During a special joint meeting of the Assembly Committee on Health and Human Services and Senate Committee on Health and Education today, lawmakers discussed four bills intended to fill gaps in Nevada’s health care system which they say put Martin and other Southern Nevadans at risk for contracting the disease.

 

“We understand that the public health system in this state depends upon public trust and the public trust was seriously eroded by this public crisis,’’ said Assemblywoman Sheila Leslie, D-Reno, who sits on the Assembly committee. The introduced bills would prevent retaliation against nurses who report breaches in patient safety, strengthen health authorities’ power during disease investigations and require annual inspections of ambulatory surgery centers and certain physician offices where conscious, general and deep levels of sedation are used.” Read more...

 

Hospitalization and disability are higher amongst HIV patients with hepatitis C coinfection

 “HIV-positive individuals co-infected with hepatitis C virus are hospitalized longer, visit emergency departments more often and spend more days disabled than people with HIV alone, according to new data presented on Tuesday at the Sixteenth Conference on Retroviruses and Opportunistic Infections in Montreal, Canada. An estimated 15% to 30% of HIV positive people also have chronic hepatitis C - though rates as high as 90% have been seen in some groups of injecting drug users. But the burden of disease and utilization of health care by co-infected patients has not been well studied.” Read more...

 

Nevada to serve as pilot state for injection safety

 “A hepatitis C outbreak in Las Vegas last year led to the discovery of a troubling lack of infection control standards in outpatient clinics nationwide. Now Nevada will be the pilot site for a national program to educate medical providers and patients about proper injection procedures. Sen. Harry Reid and Rep. Shelley Berkley will announce the initiative to promote injection safety Wednesday in Washington. The goal of the "One and Only" campaign is to prevent syringes from being reused -- a dangerous practice that can spread infectious disease.” Read more...

 

Infectious diseases kill 600 in China in January.

 “Infectious diseases killed 603 people in China in January, 600 fewer than the previous month, the Health Ministry said here Tuesday.     The mainland recorded four deaths from human bird flu in the month and 20 cases of cholera with no fatalities, it said. AIDS, tuberculosis, rabies, hepatitis B and hepatitis C were the top five killers, causing almost 90 percent of the deaths.” Read more...

 

Fundraiser for Smithfield's Kurt Beach

 “SMITHFIELD, Va. - Filling the belly for a good cause. Sunday hundreds showed their love for a Smithfield Police Officer who is in need of a new liver. Friends held a bar-b-que and turnout out was unexpected. "That gentleman in the white shirt will give you a plate," said one worker. The town Smithfield gathered for a good old fashion picnic. "It's more than we ever imagined," said organizer Sonja Pruitt. They're here not just to eat, but to raise money for someone special. "The town has been so generous," said Tracy James. "He has Hepatitis C and he needs a liver transplant," added Pruitt.” Read more...

 

Time to lift the federal ban on syringe exchange: Advocates call on Obama to fulfill campaign pledge

 “Domestic prevention advocates and members of Congress are calling on President Obama to fulfill a campaign promise by acting swiftly to lift the federal ban on funding for syringe exchange programs. The ban, which has been in place for some 20 years, prevents federal funds from being used to support a health intervention universally recognized as being highly effective in stopping the spread of HIV and hepatitis C, and as a means for reaching drug users for other interventions.  It is another in a long line of ideologically-driven restrictions on basic prevention programs which must be removed in US policy, both domestically and internationally.” Read more...

 

Negligence spreads hepatitis C in US

 “Hepatitis is a virus that causes inflammation of the liver and produces a variety of symptoms. Over 60,000 people have been exposed and 400 infected with hepatitis C in US due to poor injection practices, a federal report says. Several US officials believe that more US citizens could be exposed to hepatitis whose names have not been registered because either they have not reported or they do not know about their illness. Apparently, a number of health care workers believed that discarding used needles was sufficient to prevent the transmission of deadly blood borne diseases, and continued administering injections with the same syringe barrel, thus enabling the potential for infection transmission. Contaminations involved 33 outbreaks and were mostly caused by violations of simple safety standards.” Read more...

 

Beaumont Army Medical Center to provide update on shots inquiry

 “ Officials are to meet Thursday at Beaumont Army Medical Center to discuss the progress of an investigation into the possible exposure of more than 2,000 diabetes patients to infectious diseases such as HIV and hepatitis, according to a center official. As of midday Wednesday, 76 percent of the 2,114 patients who might have been exposed through the improper use of an insulin pen had been contacted, officials said. Of that number, 71 percent have come in for testing to see whether they have contracted any of the diseases, officials said.” Read more...

 

Hepatitis C is killing liver cells

 “It has long been thought that liver disease in hepatitis C patients is caused by the patient's immune system attacking the infected liver, ultimately killing the cells. University of Alberta researchers have discovered something different though. Michael Joyce and his team transplanted human liver cells into mice, which lack an adaptive immune system. The researchers then infected the liver cells with the hepatitis C virus. The researchers found that the virus itself damages liver cells and leads to liver cell death. They also found hepatitis C causes inflammation, which is the second step in liver disease.

Joyce's finding sheds new light on the virus and gives researchers more targets for therapy.” Read more...

 

Local organizations meeting AIDS pandemic head on

“Laquisha began using drugs and having unprotected sex when she was 15. When she turned 16, she was diagnosed with full-blown AIDS. “At that time in my life, I just didn’t care,” Laquisha said in a testimonial provided to the L.A. Watts Times, not providing her real name. “In the beginning my boyfriend and I didn’t use condoms. I contracted Hepatitis C.” Laquisha soon became homeless, and with no safe place to live the streets became her home, where she did anything to earn money to support her habit. “I … did all kinds of things to make money for my drugs,” she said. “Often times what I was doing wasn’t safe.”  Almost dead from AIDS, Laquisha finally started turning her life around. Now, five years later, she is clean and sober and successfully living with AIDS.” Read more...

 

Grant funds liver cancer research

 A University of Iowa assistant research scientist in internal medicine is leading a study funded by a $30,000 American Cancer Society seed grant through Holden Comprehensive Cancer Center at UI. Dr. Zhaowen Zhu's team will study whether and how three hepatitis C proteins increase the activity of telomerase as a possible explanation for how hepatitis C causes cancer. Hepatitis C affects about four million Americans and causes liver cirrhosis. In some patients with this type of cirrhosis, liver cancer may develop, but how this happens is not clear. Telomerase is an enzyme that promotes the longevity of most cells, including liver cells, and has been associated with the development of cancer.” Read more...

 

 

Experts raise concerns over unsuspected hepatitis C

 “An estimated 100,000 people in England are unsuspecting carriers of hepatitis C, according to a British health officer. Experts agree that there is a need for increased public awareness to dispel the myths surrounding hepatitis C and remove the social stigma that comes with the disease.” Read more...

 

New York urges testing for possible exposure to HIV

 “The New York State Health Department is urging anyone who has had sexual contact with Nassau County resident Robert Musmacker, who has told authorities he is infected with HIV, to be tested for HIV, other sexually transmitted diseases, Hepatitis B and Hepatitis C as soon as possible. Additionally, anyone who has had sexual contact with other persons who may have had sexual contact with Mr. Musmacker should also be tested.”  Read more...

 

Eleven patients infected with hepatitis C in Bulgarian Hospital

 “11 patients were infected with Hepatitis C in the hospital in Bulgaria's Teteven.   Eleven patients have been infected with Hepatitis C in the Municipal Hospital in the Bulgarian town of Teteven, Bulgarian National Television reported Friday. The intra-hospital infection most likely resulted from the use of one and the same syringe for arterial transfusion due to negligence on part of the hospital staff, according to Dr. Madlena Boyadzhieva, manager of the hospital.” Read more...

 

Eiger BioPharmaceuticals Raises $7.1 Million 'A' Round

Funding to advance novel Hepatitis C Virus (HCV) therapies against new targets

“Eiger BioPharmaceuticals, Inc., a start-up biotechnology company developing antiviral therapies, announced that it has raised $7.1 million in a Series A financing co-led by InterWest Partners and Vivo Ventures. The two firms were instrumental in the formation of the company and recruitment of its team and are represented on the board of directors by general partners Nina Kjellson and Dr. Edgar Engelman, respectively. The funding will advance the company's lead program targeted against NS4B, a specific region in the hepatitis C virus (HCV) protein, as well as progress lead identification for other proprietary targets.” Read more...

 

Martin County fire-rescue mourns firefighter's death firefighter dies from disease contracted while on duty

MARTIN COUNTY, Fla. – “The Martin County Fire-Rescue Division is mourning the loss of one of its own. Fred Pierno Jr. died Wednesday at his Port Saint Lucie home due to an illness he contracted on the job. He is the first firefighter to die in the line of duty in the history of the agency. Pierno has been under medical treatment since October 2006 for a Hepatitis C Virus infection he sustained while performing his firefighter duties. He's the 13th firefighter in the United States and the seventh in Florida to be classified as a line of duty death due to a hepatitis infection.”  Read more...

 

Canadian nurse honored for work with hepatitis C patients

 “The Canadian Association of Hepatology Nurses is honoring Fran Falconer with its clinical practice award for her 14 years of helping hepatitis C patients. Falconer says she became an advocate for hepatitis C patients when she saw an increase in the number of people seeking treatment for it and the fear and stigma associated with the disease. She continues to work to dispel myths and misconceptions about hepatitis C.” Read more...

 

 

Alcohol, hepatitis C: Dangerous cocktail

“Patients infected by the virus can develop liver cancer if they drink too much liquor, Keck School researchers find. A new study led by researchers at the Keck School of Medicine of USC found that drinking alcohol greatly increases the chances that a patient infected by the hepatitis C virus will develop a common type of liver cancer.” Read more...

 

Infected blood tragedies

 “Failures at the heart of Government led to thousands of patients being infected with HIV and Hepatitis C from tainted blood, an independent inquiry concluded yesterday. The Archer inquiry described the scandal as an “horrific human tragedy”, and said public health authorities had been “lethargic” in the 1970s and 1980s. It is estimated 4,670 haemophiliacs – who need regular blood transfusions – became infected with hepatitis C, and 1,243 contracted HIV. Some 1,800 are thought to have died.

 

The problems date from a 1975 decision to delay making the UK self-sufficient in blood products. But heat treatment of the blood to reduce the chances of infection was only introduced in 1985. During that period the NHS bought blood from US suppliers who used “Skid Row” donors, such as prison inmates, more likely to have HIV and Hepatitis C. The report said: “It is difficult to avoid the conclusion that commercial interests took precedence over public health concerns.””Read more...

 

Japan's Toray testing altered interferon for hepatitis C virus

 “Toray Industries Inc. and a research team from the University of Tokyo have begun clinical trials on a modified form of interferon beta for treatment of hepatitis C. This version of interferon beta is stabilized with PEG in a targeted manner to cloak the compound from the immune system. In tests using rabbits, unmodified interferon beta was eradicated from the blood in just a day, whereas Toray's PEG-modified interferon beta remained for six days. This suggests it might be possible to treat hepatitis C with weekly subcutaneous injections. Tests in monkeys, mice and cultured human cells have confirmed the compound's safety, durability, and ability to inhibit the proliferation of the hepatitis C virus.” Read more...

 

Clinical Trials, Cohort Studies, Pilot Studies

 

The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C.
Corey KE, Shah N, Misdraji J, et al.  Liver Int. 2009 Feb 6. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19220742?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Low weight predicts neutropenia and peginterferon alfa-2a dose reductions during treatment for chronic hepatitis C. Rotman Y, Katz L, Cohen M, et al. J Viral Hepat. 2009 Feb 11. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19220735?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Natural course of treated and untreated chronic HCV infection: results of the nationwide Hepnet.Greece cohort study. Manesis EK, Papatheodoridis GV, Touloumi G, et al. Aliment Pharmacol Ther. 2009 Feb 16. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/19222410?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Impact of early viral kinetics on pegylated interferon alpha 2b plus ribavirin therapy in Japanese patients with genotype 2 chronic hepatitis C. Nomura H, Miyagi Y, Tanimoto H, Ishibashi H. J Viral Hepat. 2009 Feb 12. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19222743?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. Grebely J, Raffa JD, Lai C, et al. J Viral Hepat. 2009 Feb 17. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/19226330?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study. Ikeda K, Kobayashi M, Someya T, et al.  J Viral Hepat. 2009 Feb 13. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/19226331?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Course of oral lichen planus: a retrospective study of 808 northern Italian patients. Carbone M, Arduino P, Carrozzo M, et al. Oral Dis. 2009 Feb 13. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19222766?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Use of supervised injection facilities and injection risk behaviours among young drug injectors. Bravo MJ, Royuela L, De la Fuente L, et al. Addiction. 2009 Feb 10. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/19215603?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Bacterial infection and neutropenia during peginterferon plus ribavirin combination therapy in patients with chronic hepatitis C with and without baseline neutropenia in clinical practice. Yang JF, Hsieh MY, Hou NJ, et al. Aliment Pharmacol Ther. 2009 Feb 7. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/19210290?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Effects of combined interferon alpha and ribavirin therapy on thyroid functions in patients with chronic hepatitis C. Nadeem A, Aslam M, Khan DA, Hussain T, Khan SA. J Coll Physicians Surg Pak. 2009 Feb;19(2):86-9.
http://www.ncbi.nlm.nih.gov/pubmed/19208310?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

 

 

Evaluation of newly developed combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon alpha-2b for advanced hepatocellular carcinoma with portal venous invasion: preliminary results. Kasai K, Kuroda H, Ushio A, et al. Hepatol Res. 2009 Feb;39(2):117-25.

http://www.ncbi.nlm.nih.gov/pubmed/19208032?ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients. Wada M, Marusawa H, Yamada R, et al. Viral Hepat. 2009 Feb 5. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19200137?ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Mutations in the interferon sensitivity-determining region of hepatitis C virus genotype 2a correlate with response to pegylated-interferon-alpha 2a monotherapy. Hayashi K, Katano Y, Honda T,et al. J Med Virol. 2009 Mar;81(3):459-66

http://www.ncbi.nlm.nih.gov/pubmed/19152412?ordinalpos=20&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response.
Akuta N, Suzuki F, Hirakawa M, et al. J Med Virol. 2009 Mar;81(3):452-8.

http://www.ncbi.nlm.nih.gov/pubmed/19152407?ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Long-term follow-up of patients with hepatitis C with a normal alanine aminotransferase.
Kumada T, Toyoda H, Kiriyama S, et al.J Med Virol. 2009 Mar;81(3):446-51

http://www.ncbi.nlm.nih.gov/pubmed/19152400?ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Mangia A, Minerva N, Bacca D, et al. Hepatology. 2009 Feb;49(2):358-63

http://www.ncbi.nlm.nih.gov/pubmed/19072829?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Treatment of hepatitis C infection for current or former substance abusers in a community setting. John-Baptiste A, Varenbut M, Lingley M, et al. J Viral Hepat. 2009 Feb 23. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22John-Baptiste%20A%22[Author]&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_HVAbstract

 

 

 

Never injected, but hepatitis C virus-infected: a study among self-declared never-injecting drug users from the Amsterdam Cohort Studies. van den Berg CH, van de Laar TJ, Kok A, et al.  J Viral Hepat. 2009 Feb 23. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19243497?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Outcome of retinopathy in chronic hepatitis C patients treated with peginterferon and ribavirin.  Mehta N, Murthy UK, Kaul V, et al. Dig Dis Sci. 2009 Feb 26. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19242801?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Coronary artery disease in patients with liver cirrhosis. Kalaitzakis E, Rosengren A, Skommevik T, Björnsson E. Dig Dis Sci. 2009 Feb 26. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19242795?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Response to antiviral therapy in liver transplant recipients with recurrent hepatitis C viral infection: a single center experience. Jain A, Sharma R, Ryan C, et al. Clin Transplant. 2009 Feb 20. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19239480?ordinalpos=10&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Factors associated with hepatic fibrosis in patients with chronic hepatitis C: A retrospective study of a large cohort of U.S. patients. Hu SX, Kyulo NL, Xia VW, Hillebrand DJ, Hu KQ. J Clin Gastroenterol. 2009 Feb 20. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19238091?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Risk of immune thrombocytopenic purpura and autoimmune hemolytic anemia among 120 908 US veterans with hepatitis C virus infection. Chiao EY, Engels EA, Kramer JR, et al. Arch Intern Med. 2009 Feb 23;169(4):357-63.

http://www.ncbi.nlm.nih.gov/pubmed/19237719?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Kirk GD, Astemborski J, Mehta SH, et al. Clin Infect Dis. 2009 Feb 23. [Epub ahead of print]

Spoler C, Fisher C, Allen D, Higgins Y, Moore RD, Afdhal N, Torbenson M, Sulkowski M, Thomas DL.

http://www.ncbi.nlm.nih.gov/pubmed/19236273?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy. Mori N, Imamura M, Kawakami Y, et al. J Med Virol. 2009 Feb 23;81(4):640-649. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19235866?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

Basic and Applied Science, Pre-Clinical Studies

 

Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy. Chehadeh W, Al-Nakib W. J Med Virol. 2009 Feb 23;81(4):610-618. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19235842?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Proapoptotic IL-18 in patients with chronic hepatitis C treated with pegylated interferon-alpha. Yingli H, Shumei L, Qian Y, Tianyan C, Yingren Z, Wei C. Clin Exp Med. 2009 Feb 24. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Yingli%20H%22[Author]&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_HVAbstract

 

Suppression of hepatitis C virus replication by protein kinase C-related kinase 2 inhibitors that block phosphorylation of viral RNA polymerase. Kim SJ, Kim JH, Sun JM, et al. J Viral Hepat. 2009 Feb 23. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19243496?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Evidence for action of ribavirin through the hepatitis C virus RNA polymerase. Cannon NA, Donlin MJ, Mayes LM, et al. J Viral Hepat. 2009 Feb 23. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19243495?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis. Kovalenko E, Tacke F, et al. J Viral Hepat. 2009 Feb 20. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Kovalenko%20E%22[Author]&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_HVAbstract

 

A liver slice culture-based ex vivo assay to predict the outcome of antiviral therapy for chronic hepatitis C. Chang ML, Sung KF, Sheen IS, Lin SM, Yeh CT. J Viral Hepat. 2009 Feb 20. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Chang%20ML%22[Author]&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_HVAbstract

 

Reduced ribavirin antiviral efficacy via nucleoside transporter-mediated drug resistance.

Ibarra KD, Pfeiffer JK. J Virol. 2009 Feb 25. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Ibarra%20KD%22[Author]&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_HVAbstract

 

The impact of hepatic steatosis on the natural history of chronic hepatitis C infection.
Cross TJ, Quaglia A, Hughes S., et al.  J Viral Hepat. 2009 Feb 5. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19200134?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

Detection of myxovirus resistance protein A in lichen planus lesions and its relationship to hepatitis C virus. Shaker OG, Hantar N, El-Tahlawi S, et al. Br J Dermatol. 2009 Feb 12. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19222461?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection. Tarantino G, Marco VD, Petta S, et al.  J Viral Hepat. 2009 Feb 5. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19200135?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

The HCV serum proteome: a search for fibrosis protein markers. Cheung KJ, Tilleman K, Deforce D, et al.. J Viral Hepat. 2009 Feb 15. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/19226329?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Site-specific cleavage of HCV genomic RNA and its cloned core and NS5B genes by DNAzyme. Kumar D, Chaudhury I, Kar P, et al.. J Gastroenterol Hepatol. 2009 Feb 4. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19220662?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV coinfected patients. Milazzo L, Meroni L, Galazzi M, et al. J Viral Hepat. 2009 Feb 7. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19215577?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum


Discovery of (R)-6-Cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a Potent and Orally Available Hepatitis C Virus Polymerase Inhibitor. Li H, Tatlock J, Linton A, et al. J Med Chem. 2009 Feb 11. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19209845?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Hepatitis C virus infection in hemodialysis patients is not associated with insulin resistance, inflammation and atherosclerosis. Caliskan Y, Oflaz H, Pusuroglu H, et al. Clin Nephrol. 2009 Feb;71(2):147-57.

http://www.ncbi.nlm.nih.gov/pubmed/19203507?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection. Mederacke I, Wedemeyer H, Manns MP. Curr Opin Investig Drugs. 2009 Feb;10(2):181-9

http://www.ncbi.nlm.nih.gov/pubmed/19197796?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Impaired plasmacytoid dendritic cell maturation and differential chemotaxis in chronic HCV: Associations with antiviral treatment outcomes. Mengshol JA Md Phd, Golden-Mason L Phd, Castelblanco N, et al. Gut. 2009 Feb 4. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Mengshol%20JA%20Md%20Phd%22[Author]&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_HVAbstract

 

Survival and hepatitis status among Asian Americans with hepatocellular carcinoma treated without liver transplantation. Hwang JP, Hassan MM. BMC Cancer. 2009 Feb 4;9:46

http://www.ncbi.nlm.nih.gov/pubmed/19193234?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Cellular immune responses during high-dose interferon-alpha induction therapy for hepatitis C virus infection. Barnes, E, Gelderblom HC, Semmo N, et al. J Infect Dis. 2009 Feb 1. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19193032?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Treatment of chronic hepatitis C: anticipated impact of resistance in patients treated with protease inhibitors. Kronenberger B, Zeuzem S.. Curr Gastroenterol Rep. 2009 Feb;11(1):15-21.

http://www.ncbi.nlm.nih.gov/pubmed/19166654?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C.
Tillmann HL, Patel K, McHutchison JG.. Curr Gastroenterol Rep. 2009 Feb;11(1):5-14.

http://www.ncbi.nlm.nih.gov/pubmed/19166653?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

HIV/HCV Coinfection

 

Comprehensive longitudinal analysis of hepatitis C virus (HCV)-specific T cell responses during acute HCV infection in the presence of existing HIV-1 infection.
van den Berg CH, Ruys TA, Nanlohy NM, et al. J Viral Hepat. 2009 Feb 12. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19222746?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Phenotypic characterization of lymphocytes in HCV/HIV co-infected patients. Roe B, Coughlan S, Dean J, et al. Viral Immunol. 2009 Feb;22(1):39-48.

http://www.ncbi.nlm.nih.gov/pubmed/19210227?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Nonalcoholic fatty liver disease among HIV-infected persons. Crum-Cianflone N, Dilay A, Collins G. et al. J Acquir Immune Defic Syndr. 2009 Feb 16. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19225402?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 Study in collaboration with the Mortalité 2005 survey, ANRS EN19). Rosenthal E, Salmon-Céron D, Lewden C, et al. HIV Med. 2009 Feb 13. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19226410?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts. Moodie EE, Pant Pai N, Klein MD.. PLoS ONE. 2009;4(2):e4517. Epub 2009

http://www.ncbi.nlm.nih.gov/pubmed/19223976?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Safety of switching nevirapine twice daily to nevirapine once daily in virologically suppressed patients. Podzamczer D, Olmo M, Sanz J. et al. J Acquir Immune Defic Syndr. 2009 Feb 12. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19214120?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

High seroprevalence but low incidence of HCV infection in a cohort of patients with sexually transmitted HIV in Andalusia (South of Spain). Palacios R, Mata R, Aguilar I, et al.

 J Int Assoc Physicians AIDS Care (Chic Ill). 2009 Feb 11. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19211932?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum


HIV-related liver disease: ARV drugs, coinfection, and other risk factors. Puoti M, Nasta P, Gatti F, et al.  J Int Assoc Physicians AIDS Care (Chic Ill). 2009 Feb 11. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19211929?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Hyaluronic acid, transforming growth factor-beta1 and hepatic fibrosis in patients with chronic hepatitis C virus and human immunodeficiency virus co-infection.  Sanvisens A, Serra I, Tural C, et al. J Viral Hepat. 2009 Feb 5. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19200132?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

Mean serum TGF-beta1 was 36.1 +/- 14.4 ng/mL; mean serum HA was 75.2 +/- 85.0 mug/L. Serum HA was positively associated and significantly correlated with the stage of fibrosis (r = 0.56; P < 0.05). The area under the curve for discriminating mild (F0-F2) from significant (F3-F4) fibrosis in receiver operating analysis using HA was 0.83 (sensitivity, 87%; specificity, 70%). These data suggest that HA is clinically useful for predicting liver fibrosis and cirrhosis in patients co-infected with HCV/HIV. However, serum TGF-beta1 was not predictive of histological damage in co-infected individuals treated with HAART.

 

Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in acute hepatitis C. Matthews GV, Hellard M, Haber P, et al. Clin Infect Dis. 2009 Mar 1;48(5):650-8.

http://www.ncbi.nlm.nih.gov/pubmed/19191653?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Complementary & Alternative Therapy

 

Involvement of hepatoma-derived growth factor in the growth inhibition of hepatocellular carcinoma cells by vitamin K(2). Yamamoto T, Nakamura H, Liu W, et al. J Gastroenterol. 2009;44(3):228-35. Epub 2009 Feb 13.

http://www.ncbi.nlm.nih.gov/pubmed/19214667?ordinalpos=8&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Hepatic fatty acid composition differs between chronic hepatitis C Patients with and without steatosis. Arendt BM, Mohammed SS, Aghdassi E, et al. J Nutr. 2009 Feb 11. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19211827?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Isoflavone consumption and subsequent risk of hepatocellular carcinoma in a population-based prospective cohort of Japanese men and women. Kurahashi N, Inoue M, Iwasaki M, et al. Int J Cancer. 2009 Apr 1;124(7):1644-9.

http://www.ncbi.nlm.nih.gov/pubmed/19089922?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Epidemiology, Diagnostics, and Miscellaneous Works

 

Hepatocellular carcinoma after sustained virologic response in hepatitis C patients without cirrhosis on a pretreatment liver biopsy. Sewell JL, Stick KM, Monto A. Eur J Gastroenterol Hepatol. 2009 Feb;21(2):225-9. http://www.ncbi.nlm.nih.gov/pubmed/19212213?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Risky sexual behavior, bleeding caused by intimate partner violence, and hepatitis C virus infection in patients of a sexually transmitted disease clinic. Russell M, Chen MJ, Nochajski TH, et al. Am J Public Health. 2009 Feb 12. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19218181?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Screening for non-alcoholic fatty liver disease (NAFLD), hepatitis B (HBV) and hepatitis C (HCV): A survey of community-based physicians. Kallman JB, Arsalla A, Park V, et al. Aliment Pharmacol Ther. 2009 Feb 10. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19220207?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Detection of hepatocellular carcinoma using glycomic analysis. Goldman R, Ressom HW, Varghese RS, et al. Clin Cancer Res. 2009 Feb 17. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19223512?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size. Craine N, Hickman M, Parry JV, et al.

Epidemiol Infect. 2009 Feb 19:1-11. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19224654?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Hepatitis C virus (HCV)-specific T-cell responses among recombinant immunoblot assay-3-indeterminate blood donors: a confirmatory evidence of HCV exposure. Bes M, Esteban JI, Casamitjana N, et al. Transfusion. 2009 Feb 12. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19222816?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Advanced recipient age (>60 years) alone should not be a contraindication to liver retransplantation. Schmitt TM, Kumer SC, Pruett TL, Argo CK, Northup PG. Transpl Int. 2009 Feb 7. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19220825?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Hepatocellular carcinoma in the Asia pacific region. Yuen MF, Hou JL, Chutaputti A. J Gastroenterol Hepatol. 2009 Feb 11. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19220670?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Long-term outcomes of donation after cardiac death liver allografts from a single center.
Nguyen JH, Bonatti H, Dickson RC, et al. Clin Transplant. 2009 Feb 11. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/19220366?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Effects of a hepatitis C virus educational intervention or a motivational intervention on alcohol use, injection drug use, and sexual risk behaviors among injection drug users.
Zule WA, Costenbader EC, Coomes CM, Wechsberg WM. Am J Public Health. 2009 Feb 12. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19218179?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Doing harm reduction better: syringe exchange in the United States. Des Jarlais DC, McKnight C, Goldblatt C, Purchase D. Addiction. 2009 Feb 10. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19215605?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Should Brazilian patients with chronic hepatitis C virus infection be vaccinated against hepatitis A virus? Villar LM, de Melo MM, Calado IA, et al.. J Gastroenterol Hepatol. 2009 Feb;24(2):238-42

http://www.ncbi.nlm.nih.gov/pubmed/19215334?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

A novel diagnostic target in the hepatitis C virus genome. Drexler JF, Kupfer B, Petersen N, et al. PLoS Med. 2009 Feb 10;6(2):e31. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19209955?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Serum ferritin as a predictor of treatment outcome in patients with chronic hepatitis C.
Ferrara F, Ventura P, Vegetti A, et al. Am J Gastroenterol. 2009 Feb 10. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19209167?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Improving survey methods in sero-epidemiological studies of injecting drug users: a case example of two cross sectional surveys in Serbia and Montenegro. Judd A, Rhodes T, Johnston LG, et al.  BMC Infect Dis. 2009 Feb 9;9(1):14. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19203380?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Alcohol and other drug treatment experiences of hepatitis C-positive and negative clients: implications for hepatitis C treatment. Brener L, Treloar CJ. Aust Health Rev. 2009 Feb;33(1):100-6.

http://www.ncbi.nlm.nih.gov/pubmed/19203339?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Amidinoanthracyclines - a new group of potential anti-hepatitis C virus compounds.
Krawczyk M, Wasowska-Lukawska M, Oszczapowicz I, et al.  Biol Chem. 2009 Feb 7. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19199832?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Temporal dynamics of a predominant protease inhibitor-resistance mutation in a treatment-naive, hepatitis C virus-infected individual. Kim AY, Timm J, Nolan BE, et al. J Infect Dis. 2009 Mar 1;199(5):737-41.

http://www.ncbi.nlm.nih.gov/pubmed/19199553?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Long-term effectiveness and cost-effectiveness of screening for Hepatitis C virus infection.
Sroczynski G, Esteban E, Conrads-Frank A, et al. Eur J Public Health. 2009 Feb 5. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19196737?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Antiviral treatment for hepatitis C virus infection: Effectiveness at general population level in a highly endemic area. Mariano A, Caserta C, Pendino GM, et al. Dig Liver Dis. 2009 Feb 2. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19196557?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Epidemiological and genetic analyses of Hepatitis C virus transmission among young/ short- and long-term injecting drug users from Rio de Janeiro, Brazil. Oliveira MD, Bastos FI, Telles PR, et al. J Clin Virol. 2009 Feb 3. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19195927?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Use of specialty care versus standard retail pharmacies for treatment of hepatitis C (February). Cohen SM, Kwasny MJ, Ahn J. Ann Pharmacother. 2009 Feb 3. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19193591?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Viral Nucleic Acid Testing (NAT) and OPO-level disposition of high-risk donor organs.
Kucirka LM, Alexander C, Namuyinga R,et al. Am J Transplant. 2009 Feb 3. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19191766?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Lay management of chronic disease: a qualitative study of living with hepatitis C infection.
Stoller EP, Webster NJ, Blixen CE, et al. Am J Health Behav. 2009 Jul-Aug;33(4):376-90.

http://www.ncbi.nlm.nih.gov/pubmed/19182983?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Gottwein JM, Scheel TK, Jensen TB, et al. Hepatology. 2009 Feb;49(2):364-77

http://www.ncbi.nlm.nih.gov/pubmed/19148942?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Transmission of hepatitis C virus in an orthopedic hospital ward. Ross RS, Viazov S, Khudyakov YE, et al. J Med Virol. 2009 Feb;81(2):249-57

http://www.ncbi.nlm.nih.gov/pubmed/19107970?ordinalpos=6&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Serum aminotransferase level and the risk of hepatocellular carcinoma: a population-based cohort study in Japan. Ishiguro S, Inoue M, Tanaka Y, et al. Eur J Cancer Prev. 2009 Feb;18(1):26-32.

http://www.ncbi.nlm.nih.gov/pubmed/19077561?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Little evidence that hepatitis C virus leads to a higher risk of mortality in the absence of cirrhosis and excess alcohol intake: the Swiss Hepatitis C Cohort Study. Prasad L, Spicher VM, Negro F, Rickenbach M, Zwahlen M; the Swiss Hepatitis C Cohort Study Group. J Viral Hepat. 2009 Feb 23. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19243494?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Access to sterile injecting equipment is more important than awareness of HCV status for injection risk behaviors among drug users. Cox J, Morissette C, DE P, Tremblay C, Allard R, Graves L, Stephenson R, Roy E. Subst Use Misuse. 2009 Feb 25:1. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19242863?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Viral hepatitis in incarcerated adults: A medical and public health concern.  Hunt DR, Saab S. Am J Gastroenterol. 2009 Feb 24. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19240708?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Health-related quality of life in methadone maintenance patients with untreated hepatitis C virus infection. Batki SL, Canfield KM, Smyth E, Ploutz-Snyder R. Drug Alcohol Depend. 2009 Feb 20. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19233573?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum